TABLE 1.
Patients’ demographic and clinicopathologic characteristics.
| Parameters | Low p-JNK | High p-JNK | χ2 | P value |
| Cases (n) | 36 | 68 | ||
| Age (years) | 0.446 | 0.504 | ||
| <46 | 15 (41.67%) | 33 (48.53%) | ||
| ≥46 | 21 (58.33%) | 35 (51.47%) | ||
| Marital status | 3.973 | 0.046 | ||
| Married | 36 (100.00%) | 62 (91.18%) | ||
| Unmarried | 0 (0.00%) | 6 (8.82%) | ||
| Family history | 0.023 | 0.880 | ||
| No | 28 (77.78%) | 52 (76.47%) | ||
| Yes | 8 (22.22%) | 16 (23.53%) | ||
| BMI | 0.042 | 0.837 | ||
| <23.77 | 18 (50.00%) | 34 (50.00%) | ||
| ≥23.77 | 18 (50.00%) | 34 (50.00%) | ||
| Menopause | 0.239 | 0.625 | ||
| No | 21 (58.33%) | 43 (63.24%) | ||
| Yes | 15 (41.67%) | 25 (36.76%) | ||
| ABO blood type | 0.105 | 0.999 | ||
| A | 10 (27.78%) | 18 (26.47%) | ||
| B | 12 (33.33%) | 22 (32.35%) | ||
| O | 9 (25.00%) | 19 (27.94%) | ||
| AB | 5 (13.89%) | 9 (13.24%) | ||
| Tumor site | 0.350 | 0.554 | ||
| Right | 17 (47.22%) | 28 (41.18%) | ||
| Left | 19 (52.78%) | 40 (58.82%) | ||
| US-Primary tumor site | 1.327 | 0.857 | ||
| Upper outer quadrant | 24 (66.67%) | 46 (67.65%) | ||
| Lower outer quadrant | 4 (11.11%) | 4 (5.88%) | ||
| Lower inner quadrant | 1 (2.78%) | 2 (2.94%) | ||
| Upper inner quadrant | 6 (16.67%) | 12 (17.65%) | ||
| Central | 1 (2.78%) | 4 (5.88%) | ||
| US-Tumor size | 0.698 | 0.705 | ||
| ≤2 cm | 9 (25.00%) | 14 (20.59%) | ||
| >2 and <5 cm | 24 (66.67%) | 45 (66.18%) | ||
| ≥5 cm | 3 (8.33%) | 9 (13.24%) | ||
| US-LNM | 0.003 | 0.960 | ||
| No | 24 (66.67%) | 45 (66.18%) | ||
| Yes | 12 (33.33%) | 23 (33.82%) | ||
| US-BIRADS | 3.654 | 0.161 | ||
| 4 | 4 (11.11%) | 6 (8.82%) | ||
| 5 | 10 (27.78%) | 32 (47.06%) | ||
| 6 | 22 (61.11%) | 30 (44.12%) | ||
| Clinical stage | ||||
| Clinical T stage | 0.218 | 0.994 | ||
| T1 | 5 (13.89%) | 8 (11.76%) | ||
| T2 | 19 (52.78%) | 37 (54.41%) | ||
| T3 | 7 (19.44%) | 12 (17.65%) | ||
| T4 | 5 (13.89%) | 11 (16.18%) | ||
| Clinical N stage | 2.582 | 0.630 | ||
| N0 | 6 (16.67%) | 14 (20.59%) | ||
| N1 | 15 (41.67%) | 18 (26.47%) | ||
| N2 | 11 (30.56%) | 25 (36.76%) | ||
| N3 | 4 (11.11%) | 11 (16.18%) | ||
| Clinical TNM stage | 0.262 | 0.877 | ||
| I | 1 (2.78%) | 3 (4.41%) | ||
| II | 14 (38.89%) | 24 (35.29%) | ||
| III | 21 (58.33%) | 41 (60.29%) | ||
| Operative time | 0.001 | 0.987 | ||
| <90 | 17 (47.22%) | 32 (47.06%) | ||
| ≥90 | 19 (52.78%) | 36 (52.94%) | ||
| Type of surgery | 0.095 | 0.758 | ||
| Mastectomy | 31 (86.11%) | 57 (83.82%) | ||
| Breast-conserving surgery | 5 (13.89%) | 11 (16.18%) | ||
| Tumor size | 0.231 | 0.891 | ||
| ≤ 2 cm | 15 (41.67%) | 30 (44.12%) | ||
| >2 and <5 cm | 19 (52.78%) | 33 (48.53%) | ||
| ≥ 5 cm | 2 (5.56%) | 5 (7.35%) | ||
| Histologic type | 0.535 | 0.465 | ||
| Ductal | 36 (100.00%) | 67 (98.53%) | ||
| Lobular | 0 (0.00%) | 1 (1.47%) | ||
| Histologic grade | 4.445 | 0.108 | ||
| I | 4 (11.11%) | 2 (2.94%) | ||
| II | 24 (66.67%) | 41 (60.29%) | ||
| III | 8 (22.22%) | 25 (36.76%) | ||
| Pathological TNM classification | ||||
| Pathological T stage | 0.264 | 0.992 | ||
| Tis/T0 | 1 (2.78%) | 3 (4.41%) | ||
| T1 | 14 (38.89%) | 24 (35.29%) | ||
| T2 | 17 (47.22%) | 33 (48.53%) | ||
| T3 | 2 (5.56%) | 4 (5.88%) | ||
| T4 | 2 (5.56%) | 4 (5.88%) | ||
| Pathological N stage | 3.468 | 0.483 | ||
| N0 | 12 (33.33%) | 18 (26.47%) | ||
| N1 | 12 (33.33%) | 15 (22.06%) | ||
| N2 | 4 (11.11%) | 9 (13.24%) | ||
| N3 | 8 (22.22%) | 26 (38.24%) | ||
| Pathological TNM stage | 2.230 | 0.681 | ||
| Tis/T0 | 1 (2.78%) | 1 (1.47%) | ||
| I | 5 (13.89%) | 11 (16.18%) | ||
| II | 16 (44.44%) | 21 (30.88%) | ||
| III | 14 (38.89%) | 35 (51.47%) | ||
| Total lymph nodes | 0.058 | 0.810 | ||
| <23 | 15 (41.67%) | 30 (44.12%) | ||
| ≥23 | 21 (58.33%) | 38 (55.88%) | ||
| Positive lymph nodes | 1.700 | 0.192 | ||
| <2 | 18 (50.00%) | 25 (36.76%) | ||
| ≥2 | 18 (50.00%) | 43 (63.24%) | ||
| Total axillary lymph nodes | 0.170 | 0.680 | ||
| <23 | 17 (47.22%) | 35 (51.47%) | ||
| ≥23 | 19 (52.78%) | 33 (48.53%) | ||
| Positive axillary lymph nodes | 1.700 | 0.192 | ||
| <2 | 18 (50.00%) | 25 (36.76%) | ||
| ≥2 | 18 (50.00%) | 43 (63.24%) | ||
| Postoperative chemotherapy | 0.421 | 0.517 | ||
| No | 4 (11.11%) | 5 (7.35%) | ||
| Yes | 32 (88.89%) | 63 (92.65%) | ||
| Postoperative radiotherapy | 0.422 | 0.516 | ||
| No | 10 (27.78%) | 15 (22.06%) | ||
| Yes | 26 (72.22%) | 53 (77.94%) | ||
| Postoperative endocrine therapy | 0.514 | 0.474 | ||
| No | 18 (50.00%) | 29 (42.65%) | ||
| Yes | 18 (50.00%) | 39 (57.35%) | ||
| Postoperative targeted therapy | 1.704 | 0.192 | ||
| No | 22 (61.11%) | 50 (73.53%) | ||
| Yes | 14 (38.89%) | 18 (26.47%) |